Nefrotoxicidade associada ao uso da Polimixina B: Revisão sistemática/ Nefrotoxicity associated with the use of Polymixin B: a systematic review

Savana Garcia de Lima, Natália Pinto Lima, Marcelo Augusto Mota Brito

Abstract


INTRODUÇÃO: A polimixina B é um antimicrobiano que entrou em desuso por apresentar alta taxa de nefrotoxicidade, mas devido ao grande crescimento de bactérias multirresistentes e a indisponibilidade de novos antibióticos, resgatou-se o seu uso.OBJETIVO: Realizar análise de aspectos de segurança do uso da polimixina B e evidenciar risco de nefrotoxicidade.MÉTODO: Estudo de revisão sistemática, de artigos publicados entre 01/01/2010 a 30/03/2021. Serão incluídos artigos do Scielo, PubMed e Lilacs. Os critérios aplicados são os do  PRISMA para redigir o relatório da revisão. Os critérios de exclusão foram artigos: duplicados; de revisão; sem especificidade com o tema; fora do período de busca e outra língua que não o inglês.RESULTADO E DISCUSSÃO: Os 23 artigos selecionados levantaram dados importantes a respeito da nefrotoxicidade da polimixina B. Em uma amostra de 2.336 pacientes que foram tratados com polimixina B, 953 (40,8%) pacientes, desenvolveram qualquer estágio de dano renal agudo e vários fatores importantes podem influenciar no desenvolvimento da nefrotoxicidade.CONCLUSÕES: A revisão sistemática enfatiza que a nefrotoxicidade é um efeito adverso presente na terapia com a polimixina B e que compreender as relações das variáveis para o desenvolvimento da lesão renal associada a terapia com a polimixina B é de vital importância para minimizar a nefrotoxicidade e otimizar o tratamento clínico.


Keywords


Nefrotoxicidade, Polimixina B, Insuficiência Renal Aguda. Efeitos Adversos.

References


Sandri AM, Landersdorfer CB, Jacob J, et al. Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens. Clin Infect Dis. 2013;57(4):524-531. Disponivel em: Acesso em:07/09/2020.

Mendes CA, Cordeiro JA, Burdmann EA. Prevalence and risk factors for acute kidney injury associated with parenteral polymyxin B use. Ann Pharmacother. 2009;43:1948–1955. 10.1345/aph.1M277 [PubMed] [CrossRef] [Google Scholar]. Disponível em:< https://sci-hub.se/https://journals.sagepub.com/doi/10.1345/aph.1M277?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed> Acesso em: 07/09/2020.

Tavares, Walter Antibióticos e quimioterápicos para o clínico/Walter Tavares. – 3. ed. rev. e atual. -- São Paulo: Editora Atheneu, 2014. Bibliografia. 1.

Antibióticos 2. Clínica médica 3. Quimioterápicos anti-infecciosos I. Título. Disponível em:< https://www.passeidireto.com/arquivo/88083718/antibioticos-e-quimioterapicos-para-o-clinico-3-edicao-walter-tavares > Acesso em : 07/09/2020.

LI, J.; RAYNER, C.R; NATION, R.L.; OWEN, R.J.; SPELMAN, D.; TAM, K.E.; LIOLIOS, L. Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii. Antimicrobial Agents Chemother. 2006; 50: 2946-50. Disponível em:< https://aac.asm.org/content/50/9/2946.long > Acesso em: 14/09/2020.

Falagas ME, Kasiakou SK: Toxicity of Polymyxins: a Sistematic Review of the Evidence from Old and Recent Studies. Critical Care. 2006; 10(1):R27 Disponível em:< https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1550802/ > Acesso em: 21/09/2020.

ZAVASCKI, A.P.; GOLDANI, L.Z.; NATION, R.L. Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review. Journal Antimicrobials Chemother. 2007; 60: 1206 – 15. Disponível em:< https://academic.oup.com/jac/article/60/6/1206/820740 > Acesso em: 21/09/2020.

POGUE, J. M.; ORTWINE, J. K.; KAYE, K. S. Are there any ways around the exposure-limiting nephrotoxicity of the polymyxins? International Journal of Antimicrobial Agents, 2016. Disponível em:< https://pubmed.ncbi.nlm.nih.gov/27876274/ > Acesso em: 21/09/2020.

VARDAKAS, K. Z.; FALAGAS, M. E. Colistin versus polymyxin B for the treatment of patients with multidrug-resistant Gram-negative infections: a systematic review and meta-analysis. International Journal of Antimicrobial Agents, v. 49, n. 2, p. 233–238, 2017. Disponível em: Acesso em: 28/09/2020.

Polymyxin B for injection. [Bula]. Estados Unidos: X-Gen Pharmaceuticals Inc. May 2005. > Acesso em: 05/10/2020.

ZAVASCKI, A.P.; GOLDANI, L.Z.; CAO, G.; SUPERTI, S.V.; LUTZ, L.; BARTH, A.L.; RAMOS, F.; BONIATTI, M.M.; NATIO, R.L.; LI, J. Pharmacokinetics of intravenous polymyxin B in critically ill patients. Clinical Infectious Diseases. 2008; 47: 1298-304. Disponível em:< https://academic.oup.com/cid/article/47/10/1298/448985> Acesso em:12/10/2020.

Mendes CAC, Burdmann EA. Polymyxins – A Review focusing on their nephrotoxicity. Rer Assoc Med Bras. 2009; 55 (6):752-759. Disponível em:< https://www.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42302009000600023&lng=en&nrm=iso&tlng=en > Acesso em:12/10/2020.

Perazella MA. Renal vulnerability to drug toxicity. Clin J Am Soc Nephrol. 2009; 4(7):1275-83 Disponível em:< https://cjasn.asnjournals.org/content/4/7/1275.long> Acesso em:19/10/2020.

PRICE, D.J.; GRAHAM, D.I. Effects of large doses of colistin sulphomethate sodium on renal function. British Medical Jounal. 1970; 4: 525-7 Disponível em:< https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1820005/pdf/brmedj02164-0033.pdf > Acesso em:19/10/2020.

Polymyxin-B and vancomycin-associated acute kidney injury in critically ill patients. Soares DS, Reis ADF, Silva Junior GBD, Leite TT, Parente Filho SLA, Rocha CVO, Daher EF.Pathog Glob Health. 2017 May;111(3):137-142. doi: 10.1080/20477724.2017.1309338. Epub 2017 Mar 29.PMID: 28353411. Disponível em:< https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5445639/ > Acesso em:02/11/2020.

Incidence of Acute Kidney Injury in Intermittent Versus Continuous Infusion of Polymyxin B in Hospitalized Patients. Alvarado Reyes Y, Cruz R, Gonzalez J, Perez Y, Wolowich WR.Ann Pharmacother. 2019 Sep;53(9):886-893. doi: 10.1177/1060028019841898. Epub 2019 Apr 11.PMID: 30971094. Disponível em:< https://sci-hub.se/https://journals.sagepub.com/doi/10.1177/1060028019841898?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed > Acesso em:09/11/2020.

Impact of polymyxin-B-associated acute kidney injury in 1-year mortality and renal function recovery. Gomes EC, Falci DR, Bergo P, Zavascki AP, Rigatto MH.Int J Antimicrob Agents. 2018 Jul;52(1):86-89. doi: 10.1016/j.ijantimicag.2018.02.016. Epub 2018 Mar 2.PMID: 29501603. Disponível em:< https://sci-hub.se/https://www.sciencedirect.com/science/article/abs/pii/S0924857918300542?via%3Dihub > Acesso em:09/11/2020.

A Comparison of Adjusted Versus Unadjusted Doses of Polymyxin B Based on Renal Function and Incidence of Acute Kidney Injury. Peyko V, Cohen H.J Pharm Pract. 2020 Jun;33(3):255-261. doi: 10.1177/0897190018798881. Epub 2018 Sep 6.PMID: 30189762. Disponível em:< https://sci-hub.se/https://journals.sagepub.com/doi/10.1177/0897190018798881?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed> Acesso em:09/11/2020.

[Risk factors for acute kidney injury in patients treated with polymyxin B experience from 139 cases at a tertiary university hospital in Colombia]. Osorio J, Barreto J, Samboni CF, Cándelo LA, Álvarez LC, Benavidez S, Téllez RP, Santofimio D, Ramos JA, Gómez CA.Rev Chilena Infectol. 2017 Feb;34(1):7-13. doi: 10.4067/S0716- 10182017000100001.PMID: 28394975. Disponível em:< https://scielo.conicyt.cl/scielo.php?script=sci_arttext&pid=S0716-10182017000100001&lng=en&nrm=iso&tlng=en > Acesso em:16/11/2020.

Incidence and predictors of acute kidney injury associated with intravenous polymyxin B therapy. Kubin CJ, Ellman TM, Phadke V, Haynes LJ, Calfee DP, Yin MT.J Infect. 2012 Jul;65(1):80-7. doi: 10.1016/j.jinf.2012.01.015. Epub 2012 Feb 2.PMID: 22326553. Disponível em:< https://sci-hub.se/https://www.journalofinfection.com/article/S0163-4453(12)00030-8/fulltext > Acesso em:16/11/2020.

Risk factors for acute kidney injury (AKI) in patients treated with polymyxin B and influence of AKI on mortality: a multicentre prospective cohort study. Rigatto MH, Behle TF, Falci DR, Freitas T, Lopes NT, Nunes M, Costa LW, Zavascki AP.J Antimicrob Chemother. 2015 May;70(5):1552-7. doi: 10.1093/jac/dku561. Epub 2015 Jan 20.PMID: 25604744. Disponível em:< https://academic.oup.com/jac/article/70/5/1552/690919 > Acesso em:16/11/2020.

Risk factors for acute kidney injury in patients treated with polymyxin B or colistin methanesulfonate sodium. Tuon FF, Rigatto MH, Lopes CK, Kamei LK, Rocha JL, Zavascki AP.Int J Antimicrob Agents. 2014 Apr;43(4):349-52. doi: 10.1016/j.ijantimicag.2013.12.002. Epub 2013 Dec 15.PMID: 24439066. Disponível em:< https://sci-hub.se/https://www.sciencedirect.com/science/article/abs/pii/S0924857913003919?via%3Dihub > Acesso em:23/11/2020.

To study the clinical efficacy and nephrotoxicity along with the risk factors for acute kidney injury associated with parenteral polymyxin B. Nandha R, Sekhri K, Mandal AK.Indian J Crit Care Med. 2013 Sep;17(5):283-7. doi: 10.4103/0972-5229.120319.PMID: 24339639. Disponível em:< https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3841490/ > Acesso em:23/11/2020.

Risk factors for acute kidney injury in patients treated with polymyxin B at a Tertiary Care Medical Center. Bahlis LF, Diogo LP, Lemons D, Klaus D.J Bras Nefrol. 2015 Oct-Dec;37(4):446-50. doi: 10.5935/0101-2800.20150071.PMID: 26648493. Disponível em:< https://www.scielo.br/scielo.php?script=sci_arttext&pid=S0101-28002015000400446&lng=en&nrm=iso&tlng=en > Acesso em:23/11/2020.

Higher incidence of acute kidney injury with intravenous colistimethate sodium compared with polymyxin B in critically ill patients at a tertiary care medical center. Akajagbor DS, Wilson SL, Shere-Wolfe KD, Dakum P, Charurat ME, Gilliam BL.Clin Infect Dis. 2013 Nov;57(9):1300-3. doi: 10.1093/cid/cit453. Epub 2013 Jul 9.PMID: 23840000. Disponível em:< https://academic.oup.com/cid/article/57/9/1300/487131 > Acesso em:30/11/2020.

Evere Infusion-Related Adverse Events and Renal Failure in Patients Receiving HighDose Intravenous Polymyxin B. John JF, Falci DR, Rigatto MH, Oliveira RD, Kremer TG, Zavascki AP.Antimicrob Agents Chemother. 2017 Dec 21;62(1):e01617-17. doi: 10.1128/AAC.01617-17. Print 2018 Jan.PMID: 29038262. Disponível em:< https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5740322/ > Acesso em:30/11/2020.

Comparison of nephrotoxicity of Colistin with Polymyxin B administered in currently recommended doses: a prospective study. Aggarwal R, Dewan A.Ann Clin Microbiol Antimicrob. 2018 Mar 23;17(1):15. doi: 10.1186/s12941-018-0262-0.PMID: 29571295. Disponível em:< https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5865377/ > Acesso em:30/11/2020.

Nephrotoxicity in Patients with or without Cystic Fibrosis Treated with Polymyxin B Compared to Colistin. Crass RL, Rutter WC, Burgess DR, Martin CA, Burgess DS.Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02329-16. doi: 10.1128/AAC.02329-16. Print 2017 Apr.PMID: 28167560. Disponível em:< https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5365730/ > Acesso em:18/02/2021.

Risk of Nephrotoxicity Associated With Nonrenally Adjusted Intravenous Polymyxin B Compared to Traditional Dosing. Maniara BP, Healy LE, Doan TL.J Pharm Pract. 2020 Jun;33(3):287-292. doi: 10.1177/0897190018799261. Epub 2018 Sep 25.PMID: 30253682. Disponível em:< https://sci-hub.se/https://journals.sagepub.com/doi/10.1177/0897190018799261?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed > Acesso em:18/02/2021.

Effect of polymyxin B-containing regimens on renal function for the treatment of carbapenem-resistant Enterobacteriacea mediastinitis. Abboud CS, Rao GG, Souza EE, Zavascki AP, Kiffer C.Braz J Infect Dis. 2018 JanFeb;22(1):51-54. doi: 10.1016/j.bjid.2017.10.006. Epub 2017 Nov 26.PMID: 29182906. Disponível em:< https://www.sciencedirect.com/science/article/pii/S1413867017307092?via%3Dihub > Acesso em:18/02/2021.

Nephrotoxicity Associated with Intravenous Polymyxin B Once- versus Twice-Daily Dosing Regimen. Okoduwa A, Ahmed N, Guo Y, Scipione MR, Papadopoulos J, Eiras DP, Dubrovskaya Y.Antimicrob Agents Chemother. 2018 Jul 27;62(8):e00025-18. doi: 10.1128/AAC.00025-18. Print 2018 Aug.PMID: 2984403. Disponível em:< https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6105789/ > Acesso em:25/02/2021.

Multicenter Prospective Cohort Study of Renal Failure in Patients Treated with Colistin versus Polymyxin B. Rigatto MH, Oliveira MS, Perdigão-Neto LV, Levin AS, Carrilho CM, Tanita MT, Tuon FF, Cardoso DE, Lopes NT, Falci DR, Zavascki AP.Antimicrob Agents Chemother. 2016 Mar 25;60(4):2443-9. doi: 10.1128/AAC.02634-15. Print 2016 Apr.PMID: 26856846. Disponível em:< https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4808237/ > Acesso em:25/02/2021.

Polymyxin B clinical outcomes: A prospective study of patients undergoing intravenous treatment. Mattos KPH, Gouvêa IR, Quintanilha JCF, Cursino MA, Vasconcelos PENS, Moriel P.J Clin Pharm Ther. 2019 Jun;44(3):415-419. doi: 10.1111/jcpt.12801. Epub 2019 Jan 21.PMID: 30666679. Disponível em:< https://sci-hub.se/https://onlinelibrary.wiley.com/doi/abs/10.1111/jcpt.12801 > Acesso em:25/02/2021.

Effectiveness and Nephrotoxicity of Intravenous Polymyxin B in Chinese Patients With MDR and XDR Nosocomial Pneumonia. Zeng H, Zeng Z, Kong X, Zhang H, Chen P, Luo H, Chen Y.Front Pharmacol. 2021 Feb 5;11:579069. doi: 10.3389/fphar.2020.579069. eCollection 2020.PMID: 33613276. Disponível em:< https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7892461/ > Acesso em:04/03/2021.

Risk factors for nephrotoxicity onset associated with polymyxin B therapy. Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH.J Antimicrob Chemother. 2015;70(6):1903-7. doi: 10.1093/jac/dkv014. Epub 2015 Feb 3.PMID: 25652747. Disponível em:< https://academic.oup.com/jac/article/70/6/1903/728513 > Acesso em:04/03/2021.

Use of polymyxin B in patients with renal impairment: A retrospective examination of 5 cases. Yu M, Zou Q, Wang H, Zheng S, Xu J, Deng X, Liu C, Zhao S, He X, Wu Q.Exp Ther Med. 2020 Nov;20(5):89. doi: 10.3892/etm.2020.9217. Epub 2020 Sep 11.PMID: 32973938. Disponível em:< https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506961/ > Acesso em:04/03/2021.

Nephrotoxicity and efficacy assessment of polymyxin use in 92 transplant patients. Mostardeiro MM, Pereira CA, Marra AR, Pestana JO, Camargo LF.Antimicrob Agents Chemother. 2013 Mar;57(3):1442-6. doi: 10.1128/AAC.01329-12. Epub 2013 Jan 7.PMID: 23295926. Disponível em:< https://aac.asm.org/content/57/3/1442.long > Acesso em:11/03/2021.




DOI: https://doi.org/10.34119/bjhrv4n3-170

Refbacks

  • There are currently no refbacks.